Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

2 May 2023

Using Intranasal Delivery for Drug Repositioning: A Compelling Proposition for Lifecy...

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
24 Apr 2023

The Potential and Challenge of Nasal Vaccination

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
20 Apr 2023

Exploring Systemic Nasal Delivery: Systems & Formulations

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
27 Mar 2023

Delivery of Biologics to the Nasal Cavity: The Future of Nasal Drug Delivery

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
1 6 7 8 9 10 27
Back To Top